U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Locally Advanced HER2-Positive Breast Carcinoma

MedGen UID:
1793709
•Concept ID:
C5557268
•
Neoplastic Process
Synonym: Locally Advanced HER2 Positive Breast Carcinoma

Definition

HER2-positive breast carcinoma that has spread from its original site of growth to nearby tissues or lymph nodes. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVLocally Advanced HER2-Positive Breast Carcinoma

Professional guidelines

PubMed

Treatment options for molecular subtypes of endometrial cancer in 2023.
Karpel HC, Slomovitz B, Coleman RL, Pothuri B
Curr Opin Obstet Gynecol 2023 Jun 1;35(3):270-278. Epub 2023 Mar 20 doi: 10.1097/GCO.0000000000000855. PMID: 36943683
Evolving management of HER2+ breast cancer brain metastases and leptomeningeal disease.
Mills MN, King W, Soyano A, Pina Y, Czerniecki BJ, Forsyth PA, Soliman H, Han HS, Ahmed KA
J Neurooncol 2022 Apr;157(2):249-269. Epub 2022 Mar 4 doi: 10.1007/s11060-022-03977-x. PMID: 35244835
Towards personalized treatment for early stage HER2-positive breast cancer.
Goutsouliak K, Veeraraghavan J, Sethunath V, De Angelis C, Osborne CK, Rimawi MF, Schiff R
Nat Rev Clin Oncol 2020 Apr;17(4):233-250. Epub 2019 Dec 13 doi: 10.1038/s41571-019-0299-9. PMID: 31836877Free PMC Article

Recent clinical studies

Etiology

Breast cancer: an up-to-date review and future perspectives.
Hong R, Xu B
Cancer Commun (Lond) 2022 Oct;42(10):913-936. Epub 2022 Sep 8 doi: 10.1002/cac2.12358. PMID: 36074908Free PMC Article
Pertuzumab retreatment for HER2-positive advanced breast cancer: A randomized, open-label phase III study (PRECIOUS).
Yamamoto Y, Iwata H, Taira N, Masuda N, Takahashi M, Yoshinami T, Ueno T, Toyama T, Yamanaka T, Takano T, Kashiwaba M, Tsugawa K, Hasegawa Y, Tamura K, Tada H, Hara F, Fujisawa T, Niikura N, Saji S, Morita S, Toi M, Ohno S
Cancer Sci 2022 Sep;113(9):3169-3179. Epub 2022 Jul 23 doi: 10.1111/cas.15474. PMID: 35754298Free PMC Article
Locally advanced breast cancer.
Aebi S, Karlsson P, Wapnir IL
Breast 2022 Mar;62 Suppl 1(Suppl 1):S58-S62. Epub 2021 Dec 15 doi: 10.1016/j.breast.2021.12.011. PMID: 34930650Free PMC Article
5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial.
Gianni L, Pienkowski T, Im YH, Tseng LM, Liu MC, Lluch A, Starosławska E, de la Haba-Rodriguez J, Im SA, Pedrini JL, Poirier B, Morandi P, Semiglazov V, Srimuninnimit V, Bianchi GV, Magazzù D, McNally V, Douthwaite H, Ross G, Valagussa P
Lancet Oncol 2016 Jun;17(6):791-800. Epub 2016 May 11 doi: 10.1016/S1470-2045(16)00163-7. PMID: 27179402
Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial.
Gianni L, Pienkowski T, Im YH, Roman L, Tseng LM, Liu MC, Lluch A, Staroslawska E, de la Haba-Rodriguez J, Im SA, Pedrini JL, Poirier B, Morandi P, Semiglazov V, Srimuninnimit V, Bianchi G, Szado T, Ratnayake J, Ross G, Valagussa P
Lancet Oncol 2012 Jan;13(1):25-32. Epub 2011 Dec 6 doi: 10.1016/S1470-2045(11)70336-9. PMID: 22153890

Diagnosis

Recently approved treatment options for patients with metastatic triple-negative and HER2-neu-positive breast cancer.
Ghafouri SR, Guvvala S, Jones C, Philipovskiy A
J Investig Med 2022 Aug;70(6):1329-1341. Epub 2022 Jun 15 doi: 10.1136/jim-2021-002298. PMID: 35705261
Evolving management of HER2+ breast cancer brain metastases and leptomeningeal disease.
Mills MN, King W, Soyano A, Pina Y, Czerniecki BJ, Forsyth PA, Soliman H, Han HS, Ahmed KA
J Neurooncol 2022 Apr;157(2):249-269. Epub 2022 Mar 4 doi: 10.1007/s11060-022-03977-x. PMID: 35244835
HER2-positive breast cancer brain metastasis: A new and exciting landscape.
Zimmer AS, Van Swearingen AED, Anders CK
Cancer Rep (Hoboken) 2022 Apr;5(4):e1274. Epub 2020 Sep 3 doi: 10.1002/cnr2.1274. PMID: 32881421Free PMC Article
Management of brain metastases according to molecular subtypes.
Soffietti R, Ahluwalia M, Lin N, Rudà R
Nat Rev Neurol 2020 Oct;16(10):557-574. Epub 2020 Sep 1 doi: 10.1038/s41582-020-0391-x. PMID: 32873927
When and how do I use neoadjuvant chemotherapy for breast cancer?
Rapoport BL, Demetriou GS, Moodley SD, Benn CA
Curr Treat Options Oncol 2014 Mar;15(1):86-98. doi: 10.1007/s11864-013-0266-0. PMID: 24306808

Therapy

Breast cancer: an up-to-date review and future perspectives.
Hong R, Xu B
Cancer Commun (Lond) 2022 Oct;42(10):913-936. Epub 2022 Sep 8 doi: 10.1002/cac2.12358. PMID: 36074908Free PMC Article
Locally advanced breast cancer.
Aebi S, Karlsson P, Wapnir IL
Breast 2022 Mar;62 Suppl 1(Suppl 1):S58-S62. Epub 2021 Dec 15 doi: 10.1016/j.breast.2021.12.011. PMID: 34930650Free PMC Article
Disitamab Vedotin: First Approval.
Deeks ED
Drugs 2021 Nov;81(16):1929-1935. doi: 10.1007/s40265-021-01614-x. PMID: 34661865
Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA).
Schneeweiss A, Chia S, Hickish T, Harvey V, Eniu A, Hegg R, Tausch C, Seo JH, Tsai YF, Ratnayake J, McNally V, Ross G, Cortés J
Ann Oncol 2013 Sep;24(9):2278-84. Epub 2013 May 22 doi: 10.1093/annonc/mdt182. PMID: 23704196
Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial.
Gianni L, Pienkowski T, Im YH, Roman L, Tseng LM, Liu MC, Lluch A, Staroslawska E, de la Haba-Rodriguez J, Im SA, Pedrini JL, Poirier B, Morandi P, Semiglazov V, Srimuninnimit V, Bianchi G, Szado T, Ratnayake J, Ross G, Valagussa P
Lancet Oncol 2012 Jan;13(1):25-32. Epub 2011 Dec 6 doi: 10.1016/S1470-2045(11)70336-9. PMID: 22153890

Prognosis

Treatment options for molecular subtypes of endometrial cancer in 2023.
Karpel HC, Slomovitz B, Coleman RL, Pothuri B
Curr Opin Obstet Gynecol 2023 Jun 1;35(3):270-278. Epub 2023 Mar 20 doi: 10.1097/GCO.0000000000000855. PMID: 36943683
Neoadjuvant Endocrine Therapy in Breast Cancer: Current Knowledge and Future Perspectives.
Barchiesi G, Mazzotta M, Krasniqi E, Pizzuti L, Marinelli D, Capomolla E, Sergi D, Amodio A, Natoli C, Gamucci T, Vizza E, Marchetti P, Botti C, Sanguineti G, Ciliberto G, Barba M, Vici P
Int J Mol Sci 2020 May 16;21(10) doi: 10.3390/ijms21103528. PMID: 32429381Free PMC Article
Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE).
Bachelot T, Ciruelos E, Schneeweiss A, Puglisi F, Peretz-Yablonski T, Bondarenko I, Paluch-Shimon S, Wardley A, Merot JL, du Toit Y, Easton V, Lindegger N, Miles D; PERUSE investigators
Ann Oncol 2019 May 1;30(5):766-773. doi: 10.1093/annonc/mdz061. PMID: 30796821
Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial.
Diéras V, Miles D, Verma S, Pegram M, Welslau M, Baselga J, Krop IE, Blackwell K, Hoersch S, Xu J, Green M, Gianni L
Lancet Oncol 2017 Jun;18(6):732-742. Epub 2017 May 16 doi: 10.1016/S1470-2045(17)30312-1. PMID: 28526536Free PMC Article
5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial.
Gianni L, Pienkowski T, Im YH, Tseng LM, Liu MC, Lluch A, Starosławska E, de la Haba-Rodriguez J, Im SA, Pedrini JL, Poirier B, Morandi P, Semiglazov V, Srimuninnimit V, Bianchi GV, Magazzù D, McNally V, Douthwaite H, Ross G, Valagussa P
Lancet Oncol 2016 Jun;17(6):791-800. Epub 2016 May 11 doi: 10.1016/S1470-2045(16)00163-7. PMID: 27179402

Clinical prediction guides

Pertuzumab, Trastuzumab, and an Aromatase Inhibitor for HER2-Positive and Hormone Receptor-Positive Metastatic or Locally Advanced Breast Cancer: PERTAIN Final Analysis.
Arpino G, de la Haba Rodríguez J, Ferrero JM, De Placido S, Osborne CK, Klingbiel D, Revelant V, Wohlfarth C, Poppe R, Rimawi MF; PERTAIN Study Group
Clin Cancer Res 2023 Apr 14;29(8):1468-1476. doi: 10.1158/1078-0432.CCR-22-1092. PMID: 36716289Free PMC Article
Neoadjuvant Endocrine Therapy in Breast Cancer: Current Knowledge and Future Perspectives.
Barchiesi G, Mazzotta M, Krasniqi E, Pizzuti L, Marinelli D, Capomolla E, Sergi D, Amodio A, Natoli C, Gamucci T, Vizza E, Marchetti P, Botti C, Sanguineti G, Ciliberto G, Barba M, Vici P
Int J Mol Sci 2020 May 16;21(10) doi: 10.3390/ijms21103528. PMID: 32429381Free PMC Article
Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial.
Tolaney SM, Wardley AM, Zambelli S, Hilton JF, Troso-Sandoval TA, Ricci F, Im SA, Kim SB, Johnston SR, Chan A, Goel S, Catron K, Chapman SC, Price GL, Yang Z, Gainford MC, André F
Lancet Oncol 2020 Jun;21(6):763-775. Epub 2020 Apr 27 doi: 10.1016/S1470-2045(20)30112-1. PMID: 32353342
Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study.
Banerji U, van Herpen CML, Saura C, Thistlethwaite F, Lord S, Moreno V, Macpherson IR, Boni V, Rolfo C, de Vries EGE, Rottey S, Geenen J, Eskens F, Gil-Martin M, Mommers EC, Koper NP, Aftimos P
Lancet Oncol 2019 Aug;20(8):1124-1135. Epub 2019 Jun 27 doi: 10.1016/S1470-2045(19)30328-6. PMID: 31257177
Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE).
Bachelot T, Ciruelos E, Schneeweiss A, Puglisi F, Peretz-Yablonski T, Bondarenko I, Paluch-Shimon S, Wardley A, Merot JL, du Toit Y, Easton V, Lindegger N, Miles D; PERUSE investigators
Ann Oncol 2019 May 1;30(5):766-773. doi: 10.1093/annonc/mdz061. PMID: 30796821

Recent systematic reviews

Effectiveness and cost-effectiveness of trastuzumab emtansine in women with HER2-positive locally advanced or metastatic breast cancer: A systematic review and meta-analysis.
Yeh Y, Chen C, Ko Y
J Cancer Res Ther 2022 Jul-Sep;18(4):1061-1072. doi: 10.4103/jcrt.jcrt_1095_21. PMID: 36149162
Management of Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases: ASCO Guideline Update.
Ramakrishna N, Anders CK, Lin NU, Morikawa A, Temin S, Chandarlapaty S, Crews JR, Davidson NE, Franzoi MAB, Kirshner JJ, Krop IE, Patt DA, Perlmutter J, Giordano SH
J Clin Oncol 2022 Aug 10;40(23):2636-2655. Epub 2022 May 31 doi: 10.1200/JCO.22.00520. PMID: 35640075
PARP (Poly ADP-Ribose Polymerase) inhibitors for locally advanced or metastatic breast cancer.
Taylor AM, Chan DLH, Tio M, Patil SM, Traina TA, Robson ME, Khasraw M
Cochrane Database Syst Rev 2021 Apr 22;4(4):CD011395. doi: 10.1002/14651858.CD011395.pub2. PMID: 33886122Free PMC Article
Recommendations on disease management for patients with advanced human epidermal growth factor receptor 2-positive breast cancer and brain metastases: American Society of Clinical Oncology clinical practice guideline.
Ramakrishna N, Temin S, Chandarlapaty S, Crews JR, Davidson NE, Esteva FJ, Giordano SH, Gonzalez-Angulo AM, Kirshner JJ, Krop I, Levinson J, Modi S, Patt DA, Perez EA, Perlmutter J, Winer EP, Lin NU
J Clin Oncol 2014 Jul 1;32(19):2100-8. Epub 2014 May 5 doi: 10.1200/JCO.2013.54.0955. PMID: 24799487Free PMC Article
Trastuzumab containing regimens for early breast cancer.
Moja L, Tagliabue L, Balduzzi S, Parmelli E, Pistotti V, Guarneri V, D'Amico R
Cochrane Database Syst Rev 2012 Apr 18;2012(4):CD006243. doi: 10.1002/14651858.CD006243.pub2. PMID: 22513938Free PMC Article

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...